- Coordinator
- South East Technological University, Ireland
- Runs
- 1 January 2025 to 31 December 2029
- Status
- Running
- EU funding
- €13.6m
- Total cost
- €23.0m
- Partners
- 30 organisations in 14 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101194784
What the project is doing
In the project's own words, from its summary on CORDIS.
BRECISE is a Public-Private Partnership Project, co-funded by the Innovative Health Initiative (IHI) of the European commission aiming at creating a collaborative ecosystem to accelerate the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) oncology biomarkers and related technologies. By addressing technical and regulatory challenges, the consortium unites diverse expertise and resources to validate novel prostate and bladder cancer biomarkers, ensuring their efficacy and clinical utility.
This initiative aligns with the goal of advancing precision medicine in oncology, ultimately improving patient outcomes and streamlining personalized cancer care. BRECISE's primary objective is to enhance biomarker-driven approaches for patient risk stratification, disease progression prediction, and treatment response assessment, within the framework of precision medicine. The project addresses the current challenge of limited access to clinically validated prognostic and predictive biomarkers in oncology.
By providing healthcare professionals with NGS-based, multi-modality AI oncology biomarkers, BRECISE aims to enable precise disease risk assessment and informed treatment selection, contributing to more personalized and effective patient care. The impact of BRECISE is transformative, aiming to revolutionize risk assessment and treatment selection in oncology, facilitating the implementation of precision medicine. This will significantly reduce unnecessary and ineffective treatments, optimizing patient care and minimizing side effects.
The validated biomarker technologies empower researchers to develop safer and more effective personalized treatments, advancing precision medicine. These advancements will enhance the competitiveness of European health industries, positioning them at the forefront of innovation and healthcare excellence. Overall, BRECISE is expected to significantly improve patient outcomes, enhance healthcare efficiency, and bolster the global standing of European health industries.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| South East Technological University | Waterford | Ireland | Coordinator |
| European Alliance for Personalised Medicine ASBL | Bruxelles / Brussel | Belgium | Participant |
| Ohmx.bio | Gent | Belgium | Participant |
| Novigenix SA | Epalinges | Switzerland | Associatedpartner |
| Pharmaledger Association | Basel | Switzerland | Associatedpartner |
| Udg Alliance | Lausanne | Switzerland | Associatedpartner |
| Bridg Ou | Tallin | Estonia | Participant |
| Elliniki Omospondia Karkinou Ell Ok | Athina | Greece | Participant |
| Atrys Health SA | Madrid | Spain | Participant |
| Fundacion Para La Investigacion De Malaga En Biomedicina Y Salud | Malaga | Spain | Third party |
| Predictby Research and Consulting S.l. | Barcelona | Spain | Participant |
| Servicio Andaluz De Salud | Sevilla | Spain | Participant |
| Universidad Complutense De Madrid | Madrid | Spain | Participant |
| Biocomputing Platforms Ltd Oy | Espoo | Finland | Participant |
| Bc Platforms | Toulouse | France | Associatedpartner |
| Mutualite Fonction Publique Action Sante Social | Paris | France | Participant |
| Genomate Health Hungary Kft | Budapest | Hungary | Participant |
| Agenzia Di Tutela Della Salute Della Brianza | Monza | Italy | Participant |
| Associazione Italiana Malati Di Cancro, Parenti E Amici | Roma | Italy | Participant |
| Dedalus Italia S.p.a. | Firenze | Italy | Participant |
| Uab Cureline Baltic | Vilnius | Lithuania | Participant |
| 3d-Pharmxchange BV | Tilburg | Netherlands | Participant |
| Crown Bioscience Netherlands BV | Leiden | Netherlands | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Hub Organoids BV | Utrecht | Netherlands | Participant |
| Philips Electronics Nederland BV | Eindhoven | Netherlands | Participant |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
| Vastra Gotalandsregionen | Vanersborg | Sweden | Participant |
| Bioclavis Limited | Clydebank | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI